U.S. Markets closed

Jazz Pharmaceuticals price target raised to $107 from $94 at Piper Jaffray

Piper Jaffray raised its price target for Jazz Pharmaceuticals to $107 citing visibility on sustained volume growth for Xyrem and keeps an Overweight rating on the stock. The firm continues to believe Jazz is attractively valued.